Enanta Pharmaceuticals, Inc.
ENTA
$0.42
Change (1 day)
$17.80
Year High
$5.70
Year Low
Categories
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. (ENTA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2024 | 6.65 M | 18.23 M | 247.84 M | 376.65 M | 299.85 M |
| 2023 | 39.62 M | -58,875,000 | 245.54 M | 462.28 M | 422.79 M |
| 2022 | 49.04 M | -18,731,000 | 54.08 M | 375.41 M | 311.71 M |
| 2021 | 60.83 M | -51,877,000 | 39.36 M | 438.79 M | 319.02 M |
| 2020 | 23.49 M | -79,032,000 | 30.55 M | 486.13 M | 436.84 M |